A Phase 2 Study of the Efficacy, Durability and Safety of Ampreloxetine (TD-9855), a Norepinephrine Reuptake Inhibitor, Given Once-daily to Treat Neurogenic Orthostatic Hypotension (nOH) in Subjects with Synucleinopathies
Objective: To assess the efficacy and durability using validated symptom questionnaire OHQ, and safety of ampreloxetine, given once-daily to treat neurogenic orthostatic hypotension (nOH) in…A Phase 2 Dose Escalation Study of Ampreloxetine (TD-9855), a Norepinephrine Reuptake Inhibitor, Given Once-Daily to Treat Neurogenic Orthostatic Hypotension (nOH) in Subjects with Synucleinopathies
Objective: To assess the acute effects of ampreloxetine on the pressor response, improvement of symptoms and safety in a daily, single, escalating doses. Background: nOH…Population Pharmacokinetics and Pharmacodynamics of Ampreloxetine (TD-9855) in Patients with Neurogenic Orthostatic Hypotension (nOH)
Objective: To characterize the Phase 2 pharmacokinetics (PK) and pharmacodynamics (PD) of ampreloxetine in patients with nOH and provide dosing recommendations for special populations in…Differences in correlation with cardiac sympathetic denervation between depression and anhedonia in drug naïve Parkinson disease patients
Objective: To compare the correlation with some assessments of DAT scan and myocardial MIBG scintigraphy between depression and anhedonia in drug naive Parkinson's Disease (PD)…Levodopa Induced Orthostatic Hypotension in Parkinson’s Disease: A Single-Dose Response Study
Objective: To determine the effect and risk factors of a single dose levodopa induced OH in PD Background: Levodopa (LD) is widely recognised as the…Droxidopa and Midodrine Treatment Persistence in Patients with Orthostatic Hypotension
Objective: To determine the treatment persistence of droxidopa and midodrine in patients with orthostatic hypotension (OH) or neurogenic orthostatic hypotension (nOH) when medication cost was…Effects of orthostatic hypotension and supine hypertension on cognition in Parkinson’s disease
Objective: The purpose of this study was to investigate the correlation of hemodynamic parameters and cognition in patients with PD. Background: Cognitive impairment is common…Preclinical cardiovascular sympathoexcitatory effects of TD-9855, a novel norepinephrine transporter (NET) inhibitor in development for the treatment of symptomatic neurogenic orthostatic hypotension (nOH) in patients with primary autonomic failure
Objective: TD-9855 is a novel NET inhibitor (1) being studied for the treatment of symptomatic nOH. The objective of the present study was to characterize…Where Are The Main Lesions That Cause Orthostatic Hypotension In Parkinson’s Disease ?
Objective: To clarify the responsible lesion of orthostatic hypotension (OH) in Parkinson’s disease (PD) by measuring the catecholamine level and using a cardiac MIBG scintigraphy.…Neurogenic Orthostatic Hypotension Burden of Illness Patient and Caregiver Survey: Impact of Symptoms
Objective: To determine the impact of neurogenic orthostatic hypotension (nOH) on the quality of life (QoL) of patients with autonomic dysfunction and the burden on…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- Next Page »